Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs DENTSPLY SIRONA Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while DENTSPLY SIRONA Inc trades at $12.26 (market cap $2.46B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 16.2× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | XRAY | |
|---|---|---|
Market Cap | $39.89B | $2.46B |
Sector | Health | Health |
52-Week High | $491.22 | $16.85 |
52-Week Low | $278.09 | $9.64 |
Enterprise Value | $38.15B | $4.60B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Dentsply Sirona (XRAY) trades at $12.26, up 3.11% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $598M in 2025, with negative profit margins and declining revenue trends. Recent news highlights distribution expansion and new AI product launches, while earnings have missed estimates for three consecutive quarters.
The outlook remains challenging with persistent losses and high debt levels, though analyst consensus suggests moderate upside to the $12.50 price target. Key risks include margin pressure and soft European demand, while potential catalysts include digital dentistry adoption and cost management under new CFO leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
